Human Monoclonal Antibodies that Bind Botulinum Toxins

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the most potent biological toxin known, the cause of the paralytic disease, botulism, and a potential bioterrorist weapon. Passive immunization with antibody therapeutics is considered to be the ideal countermeasure for a BoNT exposure, and the safest of these would be composed of human monoclonal antibodies. An important obstacle to the production of an effective antibody therapeutic strategy for BoNT is that BoNT exists in at least 7 serotypes, and most of the antibodies cloned thus far are not able to bind more than one serotype. In addition, effective neutralization requires that triplet combinations of antibodies be employed, so that neutralization of 3 toxin serotypes would require at least 9 distinct antibodies. This project addresses this problem by exploring a platform for the creation of human monoclonal antibody therapeutics capable of binding and neutralizing three distinct serotypes of BoNT, A, B, and E. The foundation of the plan is a hybridoma method of human antibody cloning that has generated a number of cross-reactive antibodies. This is combined with a novel means of increasing the in vivo potency of BoNT antibodies using a fusion peptide that may increase the rate of clearance of BoNT from the bloodstream. An important aspect of the study is an ultra-high sensitivity ELISA, developed using human monoclonal antibodies, which will allow pharmacokinetic study of low doses of BoNT bound to antibody:fusion peptide complexes in real-world in vivo exposure scenarios.